Breakthroughs in Bladder Cancer Treatment Show Promising Results
TL;DR
Pharma companies Pfizer, Merck, and Astellas reported promising results from a study showing that their drug combination of Padcev and Keytruda significantly extends survival and reduces recurrence in muscle-invasive bladder cancer patients, offering new hope for treatment options.
- The 'Enormous New Hope' In Bladder Cancer Treatment Investor's Business Daily
- Astellas-Pfizer's combination therapy halves risk of death in bladder cancer patients Reuters
- ESMO 2025 – Padcev plus Keytruda sets the perioperative bar | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
- ESMO: Keytruda, Padcev reduce risk of death by 50% in another massive showing in bladder cancer Fierce Pharma
- KEYNOTE-905: EV/pembrolizumab emerges as new option for cisplatin-ineligible MIBC Urology Times
Want the full story? Read the original reporting
Read on Investor's Business Daily